CD19 and congenital rubella syndrome: The toxicities of CAR-T cell therapy include cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), cytopenias, and B-cell aplasia (related to CD19 targeting CART cells).